#USA #New York #Investor Rights #Bronstein Gewirtz #Regeneron Pharmaceuticals

Legal Action Announced Against Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a significant legal challenge as Bronstein, Gewirtz & Grossman, LLC, a prominent law firm known for advocating investor rights, has filed a class-action lawsuit on behalf of investors. The firm accuses Regeneron and certain executives of breaching federal securities laws, urging affected parties to come forward.

Key Details of the Class Action Lawsuit

The lawsuit targets investors who purchased or acquired Regeneron securities between August 1, 2025, and May 15, 2026. Those who believe they have suffered damages during this period are encouraged to participate in the case. The firm elucidates that the lawsuit alleges that throughout the class period, Regeneron made materially false or misleading statements regarding the outcomes of clinical studies, which fundamentally impacted the company’s stock value.

Allegations Against Regeneron

The core accusations revolve around Regeneron's Phase III Fianlimab-Libtayo study. Among the key points outlined in the lawsuit are:

• - The preliminary statistical assumptions underpinning the study were flawed;
• - The treatment arm of the study failed to show significant clinical differentiation from existing treatments;
• - The study was unlikely to achieve statistical significance for its primary endpoint, even without overperformance by the control group.

These points indicate that the disclosures made by the company regarding the study's design, progress, and prospects were misleading throughout the designated period, impacting investor confidence and security values.

Next Steps for Affected Investors

Investors interested in reviewing the complaint can access it through the law firm's website at bgandg.com/REGN. For those affected by the situation, it is essential to note that September 14, 2026, is the deadline to request appointment as lead plaintiff. However, participation in potential recovery does not require lead plaintiff status.

No Financial Risk to Investors

Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning clients will not incur upfront costs. Compensation is only sought if the court rules in favor of a recovery, alleviating financial risks for investors who have suffered losses related to Regeneron’s securities.

Why Choose Bronstein, Gewirtz & Grossman, LLC?

This law firm boasts a solid reputation for obtaining significant recoveries for investors nationwide, focusing primarily on securities fraud class actions and derivative suits. According to Peretz Bronstein, the founding partner, their mission is to restore capital for investors and ensure accountability among corporations to maintain market integrity.

Stay Updated

For ongoing updates regarding this case and other potential investor issues, individuals can follow the firm on various social media platforms such as LinkedIn, X, Facebook, and Instagram.

This class action presents a crucial opportunity for investors to seek justice and compensation for their losses relating to Regeneron Pharmaceuticals. As the legal proceedings unfold, staying informed and proactive will be vital for affected parties.

For further inquiries, contact Peretz Bronstein or Client Relations Manager Nathan Miller at Bronstein, Gewirtz & Grossman, LLC at 917-590-0911.